VimpelCom Ltd (ADR) (NYSE:VIP)’s stock had its “equal weight” rating reaffirmed by research analysts at Barclays in a report released on Friday, AnalystRatingsNetwork reports. VimpelCom Ltd (ADR) (NASDAQ:VIP) net profit margin is 8.90% and weekly performance is -5.96%. On last trading day company shares ended up $7.73. Analysts mean target price for the company is $10.11. VimpelCom Ltd (ADR) (NASDAQ:VIP) distance from 50-day simple moving average (SMA50) is -9.94%.
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, announced results for its fiscal 2014 first quarter (Q1’14) ended March 31, 2014. MELA Sciences reported a Q1’14 net loss of approximately $8.0 million, or $0.16 per share, compared with a net loss of approximately $6.5 million, or $0.17 per share for the comparable period last year. Included in the Q1’14 financial results were liquidated damages of approximately $3.4 million incurred and paid in connection with the Company’s financing completed in February 2014. MELA Sciences Inc. (NASDAQ:MELA) shares fell -5.96% in last trading session and ended the day on $0.385. MELA return on assets is -121.00%.MELA Sciences Inc. (NASDAQ:MELA) quarterly performance is -47.26%.
Interval Leisure Group (NASDAQ:IILG) CEO Craig M. Nash bought 25,000 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were purchased at an average cost of $21.06 per share, for a total transaction of $526,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 647,713 shares in the company, valued at approximately $13,640,836. Interval Leisure Group, Inc. (NASDAQ:IILG) shares moved down -0.82% in last trading session and was closed at $19.47, while trading in range of $19.12 – $19.60. Interval Leisure Group, Inc. (NASDAQ:IILG) year to date (YTD) performance is -36.74%.
Foundation Medicine, Inc. (NASDAQ:FMI) announced that 17 abstracts highlighting new clinical data on FoundationOne® and FoundationOne Heme will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2014 in Chicago. Foundation Medicine Inc. (NASDAQ:FMI) ended the last trading day at $20.36. Company weekly volatility is calculated as 8.43% and price to cash ratio as 4.61.Foundation Medicine Inc. (NASDAQ:FMI) showed a negative weekly performance of -12.62%.
Leave a Reply